Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World

Biological drugs have prompted a revolution in the treatment of patients with psoriasis because of their favourable efficacy/risk profile. The aims of our study are to determine whether there is any difference in the pattern of use of biological treatments for older (65+ years) and younger patients diagnosed with plaque psoriasis by the Dermatology Service of the Hospital Universitario de Asturias (HUCA), to understand the survival of these drugs, and to identify the factors that predict the discontinuation of treatments. We report a retrospective observational hospital-based study of 300 patients registered at HUCA’s Dermatology Service who were receiving one of the following biological treatments for psoriasis on 30 November 2020: adalimumab, ustekinumab, secukinumab, or ixekizumab. The age groups were compared using Student’s t-test for quantitative variables and the chi-squared test for qualitative variables. We used the Kaplan–Meier estimator to estimate the survival function and the log-rank test to measure differences. No statistically significant differences in the frequency of use were noted between the younger and older groups, for any of the drugs studied. Survival on a drug regime, globally and individually, was similar in the two age groups. Factors predicting lower overall survival were being female, obesity, and having undergone previous biological treatment. The first three factors were influential in the under-65-year-old group, while arthritis was a significant factor for the older group.

Download Full-text

Impact of COVID19 pandemic on treatment outcome of locally-advanced head and neck squamous cell carcinoma (LA-HNSCC): IMPACCT study.

Journal of Clinical Oncology ◽

10.1200/jco.2021.39.15_suppl.6061 ◽

2021 ◽

Vol 39 (15_suppl) ◽

pp. 6061-6061

Author(s):

Pau Guillen Sentis ◽

Carmen Castillo Manzano ◽

Beatriz Quirós ◽

Francisca Morey Cortes ◽

Sara Tous ◽

...

Keyword(s):

Negative Impact ◽

Locally Advanced ◽

Standard Of Care ◽

Stage Iii ◽

Rank Test ◽

Historical Cohort ◽

First Semester ◽

Kaplan Meier ◽

Chi Squared ◽

One Year

6061 Background: Treatment (ttm) of cancer patients (pts) was compromised during the first wave of COVID19 pandemic due to collapse of healthcare systems. Standard of care (SOC) for LA-HNSCC pts had to be adapted as operating rooms were temporarily unavailable, and to reduce risk of COVID19 exposure. The IMPACCT study evaluated the outcome of LA-HNSCC pts treated at the Catalan Institute of Oncology during the first semester of 2020 and compared it to a control cohort previously treated in the same institution. Methods: Retrospective single institution analysis of two consecutively-treated cohorts of newly-diagnosed HNSCC pts: from January to June of 2020 (CT20) and same period of 2018 and 2019 (CT18-19). Pt demographics and disease characteristics were obtained from our in-site prospective database. Ttm modifications from SOC as per COVID19-contingency protocol in CT20 for LA-HNSCC were collected. Chi-squared was used to compare variables and ttm response between cohorts. One-year recurrence-free survival (1yRFS) and overall survival (1yOS) of LA-HNSCC pts were estimated by Kaplan-Meier method and compared by Log-rank test. Results: A total of 306 pts were included: CT20=99; CT18-19=207. Baseline characteristics were balanced between cohorts (Table1). In pts treated with conservative ttm (non-surgical approach), persistence disease was higher in CT20 vs CT18-19 (26 vs. 10% p=0.02). Median follow-up of CT20 and CT18-19 was 6.8 months (IQR 5.1-7.9) and 12.3 (6.7-18.4), respectively. A trend towards lower 1yRFS and 1yOS was observed in CT20 vs CT18-19 (72 vs 83% p=0.06; 80 vs 84% p=0.07), respectively. Within CT20, 37 pts (37%) had one or more ttm modifications: switch from surgery to conservative ttm (n=13); altered radiotherapy fractionation (n=14); reduced cisplatin cumulative dose to 200mg/m2 (n=19); no adjuvant ttm (n=1). Pts who received modified ttm had no differences in 1yRFS vs those who did not (80 vs 66% p=0.31), but higher 1yOS was observed (97 vs 67% p<0.01). When stratified by stage, 1yOS difference remained significant in stage III/IVA (100 vs 61% p<0.01) but not in I/II (100 vs 77% p=0.28) or IVB (67 vs 50% p=0.54). Conclusions: COVID19 pandemic had a negative impact on ttm outcomes and survival in LA-HNSCC pts when compared to our historical cohort. Ttm modifications based on COVID19-contingency protocol did not compromise ttm efficacy in terms of RFS and was associated with better OS in Stage III/IVA.[Table: see text]

Download Full-text

Outcome of surgical resection for pathologic Nx and N0 non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.7513 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. 7513-7513

Author(s):

R. U. Osarogiagbon ◽

J. W. Allen ◽

A. Farooq ◽

M. Ninan ◽

T. W. Ratliff

Keyword(s):

Surgical Resection ◽

Lung Resection ◽

Small Cell ◽

Rank Test ◽

Small Cell Lung ◽

Survival Estimate ◽

Kaplan Meier ◽

Radio Therapy ◽

Chi Squared ◽

Analysis Survival

7513 Background: Metastasis to lymph nodes (LN) connotes poor prognosis in NSCLC. Sufficient LN must be examined to accurately determine LN negativity. Patients with no LN examined (pNx) may be incompletely staged and erroneously assigned to a low risk group. To evaluate this possibility, we compared the survival of patients with node negative disease and at least 1 LN examined (pN0) to those with pNx. Methods: Retrospective analysis of all resections for NSCLC from January 1, 2004 to December 31, 2007 identified through a search of pathology databases at hospitals in the Memphis Metropolitan Area. Benign and metastatic disease, pre-operative chemo/radio therapy, bronchoalveolar cell, small cell lung, carcinoid tumors and repeat lung resection were excluded. Date of death was obtained from a National Death Index search. Variables were compared by chi-squared test, survival estimates calculated by Kaplan Meier analysis, survival estimates compared by log-rank test. Results: 746 of 809 resections met inclusion criteria. 86 (11.5%) were pNx and 510 (68.4%) pN0. Demographic and histologic characteristics were similar ( Table 1 ). 55.8% of the pNx group had sublobar resection, compared to 5.7% of pN0 (p<0.0001). 179 pN0 patients (35.1%) had only hilar-intrapulmonary LN (stations 10–14), median 3 (range 1–18) examined. 46 patients (9.02%) had only mediastinal LN (stations 1–9), median 2 (1–13); 281 patients (55.1%) had both stations 10–14 and 1–9, median 7 (2–45). 85% of pN0 patients had <10 LNs examined. 3-year survival estimate for the T1NxM0 vs T1N0M0 patients was 69% vs 70% (p= 0.14); for T2NxM0 vs T2N0M0 it was 25% vs 65% (p <0.01). Conclusions: A high percentage of patients (11.5%) undergoing surgical resection for NSCLC had pNx. These patients were more likely to have sublobar resections. Most (85%) patients with pN0 had <10 nodes examined and a large proportion (35.1%) had no mediastinal LNs, raising the possibility of understaging. Patients with pT2NxM0 did significantly worse than those with pT2N0M0. [Table: see text] [Table: see text]

Download Full-text

Association of medical comorbidities and cardiovascular disease with toxicity and survival in patients receiving checkpoint inhibitor immunotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2020.38.15_suppl.7039 ◽

2020 ◽

Vol 38 (15_suppl) ◽

pp. 7039-7039

Author(s):

Andrew Johns ◽

Lai Wei ◽

Madison Grogan ◽

Sandipkumar Patel ◽

Mingjia Li ◽

...

Keyword(s):

Cardiovascular Disease ◽

Adverse Events ◽

Advanced Cancer ◽

Checkpoint Inhibitor ◽

Rank Test ◽

Bivariate Analysis ◽

Medical Comorbidities ◽

Kaplan Meier ◽

Chi Squared ◽

Icd 10

7039 Background: Checkpoint inhibitor immunotherapy (IO) is widely used to treat advanced cancer in pts. with medical comorbidities (MC), but the effect of MC on outcomes is poorly understood. Methods: We performed a single institution retrospective cohort study of pts. who received IO from 2011-2018. Immune-related adverse events (irAEs) were graded by Common Terminology for Adverse Events criteria, v4.0. MC were abstracted by query of ICD-10 codes corresponding to diagnoses in the Charlson Comorbidity Index (CCI) at any time prior to IO start. Modified CCI scores excluding points for cancer were calculated for each pt. Bivariate analysis with chi-squared statistics was used to describe characteristics and MC of pts. with vs. without irAEs. Overall survival (OS) was estimated by the Kaplan-Meier method (from start of first-line IO) and compared using the log-rank test. The association of CCI score and individual MC with irAEs and OS was tested with regression models adjusted for pt. characteristics. Results: Among 671 pts. with advanced cancer (39.6% melanoma; 21.8% non-small cell lung) treated with IO, median age 65 (IQR 55-74) years, the most common MC were COPD (24%) and diabetes (20%). 33.8% of pts. had CCI score ≥2. Neither CCI score nor any specific MC were associated with any grade or ≥G3 irAEs (P > 0.05). Increasing CCI score was significantly associated with decreased OS (P = 0.002). CHF (13.9 vs. 8.1 months, P = 0.008) and previous MI (14.2 vs. 10.1 months, P = 0.009) were associated with decreased median OS but did not remain significant in the regression model. Among pts. without cardiovascular disease (CVD), pts. with ≥G3 irAEs had longer OS than pts. with no ≥G3 irAEs (P < 0.001). This OS benefit for ≥G3 irAEs was not seen in pts. with CVD (P = 0.94). See table for adjusted HR. Conclusions: Risk for irAEs does not appear to be impacted by MC. Pts. with MC have shorter OS, but no specific MC are associated with OS after adjustment for pt. characteristics. OS is significantly increased among pts. without CVD who experience ≥G3 irAEs. CVD may be an important predictor of OS in pts. with irAEs and should be evaluated in patients receiving IO. [Table: see text]

Download Full-text

BOND FAILURE RATE OF AMORPHOUS CALCIUM PHOSPHATE CONTAINING (AEGIS ORTHO) AND FLUORIDE RELEASING (TRANSBOND PLUS COLOUR CHANGE) ORTHODONTIC ADHESIVES-A RANDOMIZED CLINICAL TRIAL

Journal of Indian Dental Association ◽

10.33882/jida.13.25277 ◽

2019 ◽

Author(s):

Shyamala Naidu ◽

Anand Suresh

Keyword(s):

Calcium Phosphate ◽

Failure Rate ◽

Amorphous Calcium Phosphate ◽

Age Groups ◽

Colour Change ◽

White Spot ◽

Rank Test ◽

White Spot Lesions ◽

Bond Failure ◽

Kaplan Meier

Background: The aim of the study was to compare the survival rate of brackets bonded with amorphous calcium phosphate containing adhesive and fluoride releasing orthodontic adhesive over 6 months period. White spot lesions were also evaluated prior to bonding, 3 months and 6 months from the date of bonding. Methods: Thirty six orthodontic patients were randomly divided into two equal groups using split mouth design. 592 brackets were bonded up to the premolars with either Aegis Ortho or Transbond Colour Change(TPCCA). Bracket failure rate and survival distribution were evaluated and compared using Kaplan- meier analysis and Log rank test with respect to adhesives, dental arches, segments , tooth types, gender and age groups. White spot lesion was assessed using WSL index. Results: There was no significant difference between the failure rate of Aegis Ortho(3.0%) and TPCCA(1.4%). Kaplan Meier analysis, Log rank test showed that the difference in the overall failure rate and survival time between the arches, gender, and different age groups were not statistically significant. Both adhesives had a high bond failure rate in the posterior segment especially in the premolar region. Three patients had white spot lesions in the upper premolar region bonded with Aegis ortho. Conclusion: Both Aegis ortho and Transbond plus colour change adhesive with a low bond failure rate can be used as an alternative orthodontic adhesive. Key words : bond failure, amorphous calcium phosphate, transbond colour change adhesive, white spot lesions.

Download Full-text

Clinical Performance of Lithium Disilicate Glass-Ceramic Onlays For The Treatment of Tooth Defects

10.21203/rs.3.rs-840869/v1 ◽

2021 ◽

Author(s):

Shujiang Chen ◽

Meng Lu ◽

Zhimin Zhu ◽

Wenchuan C. Chen

Keyword(s):

Survival Rate ◽

Glass Ceramic ◽

Clinical Performance ◽

United States Public Health ◽

Lithium Disilicate ◽

Western China ◽

Rank Test ◽

Log Rank Test ◽

Kaplan Meier ◽

Chi Squared

Abstract BackgroundThe aim of this study was to assess the clinical performance of lithium disilicate glass-ceramic onlays for the treatment of tooth defects and to evaluate the clinical performance and whether they are worth more extensive use as that of the full crown. MethodsPatients who received treatment by lithium disilicate glass-ceramic onlays at the Western China Hospital of Stomatology were recalled after 1~4 years. The clinical performance and patients’ satisfaction of onlays for various tooth defects, cracked or uncracked teeth and endodontically treated or vital teeth were retrospectively evaluated with a combination of modified United States Public Health Service Criteria and questionnaire survey. Statistical analysis was performed by using the chi-squared test, Kaplan–Meier analysis and Log-rank test (a = 0.05) where appropriate. ResultsA total of 154 patients with 166 onlays were recalled for clinical examination. Of the 166 onlays examined, 65 (39.19%) were occlusal onlays, 92 (55.42%) were proximal-occlusive onlays and 9 (5.42%) were buccal-or lingual-occlusal onlays. The clinical performance of O and PO onlays was not significantly different (P > 0.05), according to USPHS Criteria. Kaplan-Meier analysis showed that the 4-year survival rate of O and PO onlays was 95.4% and 97.8%, respectively while there was no failure happened in buccal-or lingual-occlusal onlays. Log- rank test showed that the kinds of defects/onlays, tooth vitality and tooth crack had no influence on the survival rate (P > 0.05). The overall satisfaction rate was more than 98%.ConclusionsThis medium-term analysis indicated that lithium disilicate glass-ceramic onlays achieved satisfactory clinical performance for the restoration of different tooth defects. The survival rate of onlays was comparable to that of full crown. Different kinds of tooth defects, tooth vitality and tooth crack did not influence performance.Trial registrationThe study was approved by the Medical Ethics Committee of West China Hospital of Stomatology of Sichuan University with the approval number: WCHSIRB-D-2021-300. Consent to participate was not applicable.

Download Full-text

Molecular Insights into the Classification of Luminal Breast Cancers: The Genomic Heterogeneity of Progesterone-Negative Tumors

International Journal of Molecular Sciences ◽

10.3390/ijms20030510 ◽

2019 ◽

Vol 20 (3) ◽

pp. 510 ◽

Cited By ~ 6

Author(s):

Gianluca Lopez ◽

Jole Costanza ◽

Matteo Colleoni ◽

Laura Fontana ◽

Stefano Ferrero ◽

...

Keyword(s):

Cancer Genomics ◽

Molecular Taxonomy ◽

The Cancer Genome Atlas ◽

Rank Test ◽

Breast Cancers ◽

Cancer Genes ◽

Kaplan Meier ◽

Er Positive ◽

Cancer Genome Atlas ◽

Student’S T

Estrogen receptor (ER)-positive progesterone receptor (PR)-negative breast cancers are infrequent but clinically challenging. Despite the volume of genomic data available on these tumors, their biology remains poorly understood. Here, we aimed to identify clinically relevant subclasses of ER+/PR− breast cancers based on their mutational landscape. The Cancer Genomics Data Server was interrogated for mutational and clinical data of all ER+ breast cancers with information on PR status from The Cancer Genome Atlas (TCGA), Memorial Sloan Kettering (MSK), and Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) projects. Clustering analysis was performed using gplots, ggplot2, and ComplexHeatmap packages. Comparisons between groups were performed using the Student’s t-test and the test of Equal or Given Proportions. Survival curves were built according to the Kaplan–Meier method; differences in survival were assessed with the log-rank test. A total of 3570 ER+ breast cancers (PR− n = 959, 27%; PR+ n = 2611, 73%) were analyzed. Mutations in well-known cancer genes such as TP53, GATA3, CDH1, HER2, CDH1, and BRAF were private to or enriched for in PR− tumors. Mutual exclusivity analysis revealed the presence of four molecular clusters with significantly different prognosis on the basis of PIK3CA and TP53 status. ER+/PR− breast cancers are genetically heterogeneous and encompass a variety of distinct entities in terms of prognostic and predictive information.

Download Full-text

Resection of intrahepatic cholangiocarcinoma in elderly patients – is it reasonable?

BMC Surgery ◽

10.1186/s12893-019-0620-7 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 2

Author(s):

Fabian Bartsch ◽

Janine Baumgart ◽

Verena Tripke ◽

Maria Hoppe-Lotichius ◽

Stefan Heinrich ◽

...

Keyword(s):

Elderly Patients ◽

Middle Age ◽

Age Groups ◽

Young Group ◽

Rank Test ◽

Term Outcome ◽

Old Patients ◽

Long Term Outcome ◽

Kaplan Meier ◽

Extent Of Surgery

Abstract Background Intrahepatic cholangiocarinoma (ICC) has a rising incidence in western countries. Often major or extended resections are necessary for complete tumor removal. Due to demographical trends the number of elderly patients diagnosed with ICC is rising accordingly. Aim of this study is to show whether resection of ICC in elderly patients is reasonable or not. Methods Between January 2008 and June 2018 all consecutive patients with ICC were collected. Analyses were focussed on the performed resection, its extent, postoperative morbidity and mortality as well as survival. Statistics were performed with Chi2 test for categorical data and for survival analyses the Kaplan Meier model with log rank test was used. Results In total 210 patients underwent surgical exploration with 150 resections (71.4%). Patients were divided in 70-years cut-off groups (> 70 vs < 70 years of age) as well as a young (age 30–50, n = 23), middle-age (50–70, n = 76) and old (> 70, n = 51) group, whose results are presented here. Resectability (p = 0.709), extent of surgery (p = 0.765), morbidity (p = 0.420) and mortality (p = 0.965) was comparable between the different age groups. Neither visceral (p = 0.991) nor vascular (p = 0.614) extension differed significantly, likewise tumor recurrence (p = 0.300) or the localisation of recurrence (p = 0.722). In comparison of patients > or < 70 years of age, recurrence-free survival (RFS) was significantly better for the younger group (p = 0.047). For overall survival (OS) a benefit could be shown, but without reaching significance (p = 0.072). In subgroup analysis the middle-age group had significant better OS (p = 0.020) and RFS (p = 0.038) compared to the old group. Additionally, a better OS (p = 0.076) and RFS (p = 0.179) was shown in comparison with the young group as well, but without reaching significance. The young compared to the old group had analogous OS (p = 0.931) and RFS (p = 0.845). Conclusion Resection of ICC in elderly patients is not associated with an increased perioperative risk. Even extended resections can be performed in elderly patients without obvious disadvantages. Middle-age patients have a clear benefit for OS and RFS, while young and old patients have a comparable and worse long-term outcome.

Download Full-text

Selecting patients with stage II/III colorectal cancer for 5-fluorouracil-based adjuvant chemotherapy using proteomic analysis.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.4_suppl.708 ◽

2018 ◽

Vol 36 (4_suppl) ◽

pp. 708-708

Author(s):

Dongyao Yan ◽

Ji Hyung Hong ◽

Hee Yeon Lee ◽

Jae Ho Byun ◽

Fabiola Cecchi ◽

...

Keyword(s):

Colorectal Cancer ◽

Mass Spectrometry ◽

Cohort Analysis ◽

Tumor Stage ◽

Stage Ii ◽

Disease Stage ◽

Rank Test ◽

Kaplan Meier ◽

Significant Difference ◽

Student’S T

708 Background: 5-fluorouracil (5-FU) is a common adjuvant treatment for stage III and high-risk stage II colorectal cancer (CRC). However, about 20% of patients relapse within 48 months of treatment with 5-FU, even when combined with oxaliplatin. To improve patient selection, tumor biomarkers that predict sensitivity to 5-FU have been proposed. These include proteins involved in 5-FU activation or metabolism such as uridine-cytidine kinase 2 (UCK2) and thymidylate synthase (TYMS). We used multiplexed mass spectrometry to evaluate the utility these biomarkers in the archived tumor samples of patients with stage II/III CRC. Methods: Tumor samples were from 143 patients with stage II/III CRC who received adjuvant 5-FU, folinic acid, and oxaliplatin during 2000-2014; 83% of patients received 12 cycles and the others received ≤ 11 cycles. Tumor cells were microdissected and solubilized, and 67 candidate biomarkers were quantitated using mass spectrometry. Overall survival (OS) and relapse-free survival (RFS) were assessed using the Kaplan-Meier method and log-rank test. Protein expression by tumor stage, lymph node (LN) status, tumor sidedness was compared using the Student’s t-test. Results: Of 143 patients, 45 had recurrence and 98 patients did not. UCK2 was detected in all samples, ranging from 187 to 1606 attomoles per microgram of total protein (amol/µg). Patients with UCK2 expression above 335 amol/μg (n = 109) had significantly longer OS than patients with lower expression (n = 34; HR: 0.42; p= 0.009). There was no significant difference in RFS (HR: 0.6; p= 0.088). UCK2 expression did not differ by disease stage, LN metastasis status, or tumor sidedness. TYMS expression was not associated with survival in this cohort. Analysis of other biomarkers associated with response to 5-FU and platinum is in progress. Conclusions: In stage II/III CRC, UCK2 expression above 335 amol/μg identifies a subgroup of 5-FU-treated CRC patients with longer survival, suggesting that quantitated UCK2 has potential for use in selecting patients for treatment. These findings warrant validation in larger cohorts.

Download Full-text

Survival in a cohort of patients with lung cancer: the role of age and gender in prognosis

Jornal Brasileiro de Pneumologia ◽

10.1590/s1806-37562016000000298 ◽

2017 ◽

Vol 43 (6) ◽

pp. 431-436 ◽

Cited By ~ 3

Author(s):

Juliana Pereira Franceschini ◽

Sérgio Jamnik ◽

Ilka Lopes Santoro

Keyword(s):

Lung Cancer ◽

Age Distribution ◽

Age Groups ◽

Rank Test ◽

Age Group ◽

Tertiary Referral Hospital ◽

Kaplan Meier ◽

Stage Disease ◽

And Gender ◽

Disease Stages

ABSTRACT Objective: To determine the demographic and clinical characteristics of patients with non-small cell lung cancer (NSCLC), as well as their disease course, by age group and gender. Methods: This was a retrospective cohort study of patients diagnosed with NSCLC from 2000 to 2012 and followed until July 2015 in a tertiary referral hospital in the city of São Paulo, Brazil. Based on the 25th and 75th percentiles of the age distribution, patients were stratified into three age groups: < 55 years; ≥ 55 and < 72 years; and ≥ 72 years. Survival time was evaluated during the follow-up period of the study. Functions of overall and gender-specific survival stratified by age groups (event: all-cause mortality) were calculated using the Kaplan-Meier method. Differences among survival curves were assessed via the log-rank test. Results: We included 790 patients with the following age distribution: < 55 years, 165 patients; ≥ 55 and < 72 years, 423; and ≥ 72 years, 202. In the entire sample, there were 493 men (62.4%). Adenocarcinoma was the most common histological pattern in the < 72-year age groups; 575 patients (73%) presented with advanced disease (stages IIIB-IV). The median 5-year survival was 12 months (95% CI: 4-46 months), with no significant differences among the age groups studied. Conclusions: NSCLC remains more common in men, although we found an increase in the proportion of the disease in women in the < 55-year age group. Adenocarcinoma predominated in women. In men, squamous cell carcinoma predominated in the ≥ 72-year age group. Most patients presented with advanced-stage disease at diagnosis. There were no statistical differences in survival between genders or among age groups.

Download Full-text

Prevalence and co-infection of schistosomiasis/hepatitis B among rural populations in endemic areas in Hubei, China

Transactions of the Royal Society of Tropical Medicine and Hygiene ◽

10.1093/trstmh/trz086 ◽

2019 ◽

Vol 114 (3) ◽

pp. 155-161 ◽

Cited By ~ 1

Author(s):

Yupeng Zhang ◽

Yaofei Xie ◽

Qi Chen ◽

Xuyu Chen ◽

Zhuangzhuang Dong ◽

...

Keyword(s):

Hepatitis B ◽

Age Groups ◽

Cross Sectional Study ◽

Hbv Infection ◽

Cross Sectional ◽

Exact Test ◽

Aged People ◽

Qualitative Variables ◽

Chi Squared ◽

Endemic Areas

Abstract Background Both hepatitis B virus (HBV) infection and schistosomiasis are important public health problems in China. Concurrent infection between HBV and schistosomiasis is often observed in areas where schistosomiasis is endemic. The aim of this study was to determine the prevalence of schistosomiasis and HBV in schistosomiasis-affected areas, to explore whether schistosomiasis patients are more susceptible to HBV and to determine if the prevalence of HBV in high-endemic areas of schistosomiasis is higher than in low-endemic areas. Methods A total of 6526 participants from 13 villages in Hubei province were included in a cross-sectional study and blood samples were collected and examined. Qualitative variables were compared between groups using Pearson’s chi-squared test or Fisher’s exact test as appropriate. Results Of the 6526 participants, the overall prevalence was 8.27% for schistosomiasis and 2.67% for HBV. The prevalence of hepatitis B among participants who were Schistosoma antibody positive (25.37%) was higher than the prevalence in participants who were Schistosoma antibody negative (0.62%; χ2=1169.358, p<0.001, odds ratio 54.659). We also observed that there was no difference in the prevalence of hepatitis B between males and females in areas where schistosomiasis was endemic (χ2=1.827, p=0.177), but the prevalence of hepatitis B in middle-aged people was higher than in other age groups (χ2=47.877, p<0.001). Conclusions There was an association between schistosomiasis and HBV infection. However, more work is needed to find the causal relationship between schistosomiasis and HBV infection.

Download Full-text